GenomePrecision Secures ￥200 Million in Series C Funding

(VCBeat) Apr. 19, 2021 -- Beijing GenomePrecision Technology Co., Ltd. ("GenomePrecision"), an overall solution provider for molecular diagnostics of hematologic diseases in China, today announced the completion of a Series C financing of RMB 200 million, jointly led by Sunland Capital and ZGC Co-Innovation Fund, with participation from Galaxy Yuanhui Investment and Guiyang Venture Capital, and existing investors Oriental Fortune Capital and Jiuren Capital continue to add investment. CEC Capital acted as the exclusive financial adviser in this transaction.

This round of financing is mainly used for the large-scale clinical trials, the application for product registration, and the marketing of molecular diagnostics products; the implementation of overall solutions in the third-grade hospitals, product R&D, and the consolidation of GenomePrecision's leading position in the field of molecular diagnostics of hematologic diseases.

Founded in 2015, GenomePrecision has been established six technology platforms for the molecular diagnostic requirements of blood disease of all levels of hospitals, covering real-time fluorescence-based quantitative PCR, first-generation Sanger sequencing, next-generation high-throughput NGS sequencing, capillary electrophoresis fragment analysis, visualized molecular pathology, and microfluidics. The company is engaged in four fields, including hematologic tumors, transplantation, new molecular pathology, and cellular immunotherapy. It provides complete molecular diagnosis, monitoring solutions, corresponding products and service chains; and supporting the whole testing needs of blood disease detection, diagnosis, efficacy evaluation and prognosis monitoring in hospitals at all levels.

Sunlan Capital is a professional fund focused on early and growing health care industry investments with offices in Shanghai and Beijing, focusing on biomedical and medical devices (in vitro diagnostics and gene technology, minimally invasive interventions, implantable devices, minimally invasive high-growth segments such as surgical instruments and medical robots, and medical services.

ZGC Co-Innovation Fund is jointly initiated and established by ZGC Development Group, and 15 local governments and financial institutions in 9 provinces and cities. The company adopts the "1+1+N" business mode -- it sets up 1 parent fund, 1 direct investment sub-fund system, and N collaborative innovation sub-funds with a total amount of 10 billion yuan.